Comparison of Single-Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies.

Abstract

Accurate preoperative lymphoscintigraphy is vital to performing sentinel lymph node biopsy (SLNB) for cutaneous malignancies. Potential advantages of single-photon emission computed tomography with integrated computed tomography (SPECT/CT) include the ability to readily identify aberrant drainage patterns as well as provide the surgeon with three-dimensional anatomic landmarks not seen on conventional planar lymphoscintigraphy (PLS). Patients with cutaneous malignancies who underwent SLNB with preoperative imaging using both SPECT/CT and PLS from 2011 to 2014 were identified. Both SPECT/CT and PLS were obtained in 351 patients (median age, 69years; range, 5-94years) with cutaneous malignancies (melanoma=300, Merkel cell carcinoma=33, squamous cell carcinoma=8, other=10) after intradermal injection of 99mtechnetium sulfur colloid (median dose 300µCi). A mean of 4.3 hot spots were identified on SPECT/CT compared to 3.0 on PLS (p<0.001). One hundred fifty-three patients (43.6%) had identical findings between SPECT/CT and PLS, while 172 (49%) had additional hot spots identified on SPECT/CT compared to only 24 (6.8%) additional on PLS. SPECT/CT demonstrated additional nodal basins in 103 patients (29.4%), compared to only 11 patients (3.1%) with additional basins on PLS. SPECT/CT is a useful adjunct that can help with sentinel node localization in challenging cases. It identified additional hot spots not seen on PLS in almost 50% of patients. Because PLS identified hot spots not seen on SPECT/CT in 6.8% of patients, we recommend using both modalities jointly. Long-term follow-up will be required to validate the clinical significance of the additional hot spots identified by SPECT/CT.